A family of powerful bioactive lipids known as leukotriene receptors (cys-LTs) act through two structurally distinct G protein-coupled receptors known as the CysLT1 and CysLT2 receptors. Important mediators of human bronchial asthma include the cysteinyl leukotrienes LTC4, LTD4, and LTE4. The second messenger system that the leukotriene receptor uses is phosphatidylinositol-calcium. It belongs to the superfamily of G protein-coupled receptors. When LTD4 activates CysLT1, smooth muscle contracts and grows more, there is oedema, eosinophil migration, and lung mucus layer damage. LTRAs, or leukotriene receptor antagonists, are a class of non-steroidal oral medications. They may also be known as bronchoconstriction preventors with anti-inflammatory properties. LTRAs function by preventing a chemical process that can result in airway inflammation.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V84100 | (5S,6S)-DiHETE | 82948-87-6 | |
|
V9950 | Ablukast (Ro23-3544) | 96566-25-5 | Ablukast (Ro 23-3544) is a novel and potent leuktriene receptor antagonist with anti-asthmatic effects. |
|
V75433 | BLT2 antagonist-1 | 2069220-61-5 | BLT2 agonist-1 (compound 15b) is a selective BLT2 antagonist that can inhibit the chemotaxis of CHO-BLT2 cells with IC50 of 224 nM. |
|
V75431 | BLT2 probe 1 | 2893803-05-7 | BLT2 probe 1 (compound 13) is a fluorescent probe based on the synthetic BLT2 agonist CAY10583. |
|
V75438 | CP-96021 hydrochloride | 167011-22-5 | CP-96021 HCl is a balanced, potent orally bioactive leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonist (inhibitor) with Kis of 34 nM and 37 nM, respectively. |
|
V5319 | CP105696 | 58081-99-3 | CP-105,696 (CP105696; CP-105696) is an orally bioactive, potent and selective leukotriene B4 receptor (LTB4R) antagonist (IC50 against [3H]LTB4 = 5.6 nM for binding human neutrophils; IC50 = 9.7 nM & 30.3 nM, respectively using guinea pig spleen or mouse membranes) that targets LTB4R high- and low-affinity binding sites in a LTB4 non-competitive and competitive manner, respectively. |
|
V75430 | FPL-55712 free base | 40785-97-5 | FPL-55712 free base is a leukotriene receptor antagonist. |
|
V51187 | HAMI-3379 | 1245653-57-9 | CysLT2 antagonist |
|
V85212 | JNJ-40929837 succinate | 1191044-47-9 | |
|
V75436 | LTB4 antagonist 1 | 2929239-84-7 | LTB4 antagonist 1 is a carboxamic acid compound that is a potent leukotriene B4 (LTB4) antagonist (inhibitor) with IC50 of 288 nM. |
|
V75437 | LTB4 antagonist 2 | 2929239-85-8 | LTB4 antagonist 2 is a carboxamic acid compound that is an antagonist of leukotriene B4 (LTB4) and has potential anti-inflammatory activity. |
|
V75432 | LTB4 antagonist 3 | 2929239-87-0 | LTB4 antagonist 3 (compound 24e) is a leukotriene B4 (LTB4) antagonist (inhibitor) with IC50 of 477 nM. |
|
V4326 | MK-571 sodium | 115103-85-0 | MK-571 sodium (L-660711; MK571) is a novel, potent, selective, orally bioactive antagonist of leukotriene D4 (LTD4) receptor with the potential to be used for pulmonary hypertension. |
|
V41728 | Montelukast Dicyclohexylamine | 577953-88-9 | Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally bioactive cysteine leukotriene receptor 1 (CysLT1) antagonist. |
|
V4387 | MONTELUKAST SODIUM (MK0476) | 151767-02-1 | Montelukast sodium (also known as MK-476; trade names Singulair; Monteflo; Lukotas; Lumona) is a novel, potent, selective CysLT1 (leukotriene receptor) receptor antagonist used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. |
|
V75428 | Montelukast-d6 (MK0476-d6 (free acid)) | 1093746-29-2 | Montelukast-d6 is the deuterium labelled form of Montelukast. |
|
V75426 | Montelukast-d6 sodium (MK0476-d6) | 2673270-26-1 | Montelukast-d6 (sodium) is the deuterated form of Montelukast (sodium). |
|
V2451 | Olsalazine Sodium (CJ-91B) | 6054-98-4 | Olsalazine Sodium (CJ-91B) is a potent anti-inflammatory prodrug, which consists of two 5-ASA moieties linked by an azo bond. |
|
V75427 | Piriprost potassium (U 60257B) | 88851-62-1 | Piriprost (U-60,257B) potassium is a leukotriene synthesis inhibitor. |
|
V4685 | Pranlukast | 103177-37-3 | Pranlukast is a potent, selective and competitive antagonist of cysteinyl leukotriene receptor-1 (CysLT1) Pranlukast with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM for inhibiting [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
